Rare diseases
Investigational molecules
Locations
Turnhoutseweg 30, 2340 Beerse, Belgium
Multiple myeloma, relapsed or refractory myeloma, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic neoplasms, and AL amyloidosis are prominent areas of interest, alongside studies in mantle cell lymphoma and other B-cell malignancies.
Research also extends to warm autoimmune hemolytic anemia and other haematology-focused conditions.
Janssen Cilag International runs clinical trials in conditions such as Plasma cell myeloma, Colitis ulcerative, Non-small cell lung cancer, Crohn's disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
AustriaStudy on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments
BulgariaStudy on Seltorexant for Adults and Elderly with Major Depressive Disorder and Insomnia Symptoms
BulgariaRamantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant
CzechiaProphylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)
FranceEfficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis
AustriaPhase 2 Neoadjuvant Study of Amivantamab with Lazertinib in Resectable EGFR‑Mutated Non‑Small Cell Lung Cancer Patients
SpainPhase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments
CzechiaA Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease
AustriaNipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
BulgariaJNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments
FranceA study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
